Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

Rhea-AI Summary

Kymera Therapeutics, Inc. (NASDAQ: KYMR) will release its fourth quarter and full year 2023 financial results on February 22, 2024. The company specializes in small molecule medicines using targeted protein degradation. Investors can join the conference call at 8:30 a.m. ET or access the webcast on the company's website.

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report fourth quarter and full year 2023 financial results on February 22, 2024, and will host a conference call at 8:30 a.m. ET.

To access the February 22 conference call via phone, please dial +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International) and ask to join the Kymera Therapeutics call. A live webcast of the Company’s conference call will be available under “News and Events” in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (previously Twitter) or LinkedIn.

Investor Contact:   Justine Koenigsberg Vice President, Investor Relations investors@kymeratx.com 857-285-5300

Media Contact:   Todd Cooper  Senior Vice President, Corporate Affairs  media@kymeratx.com  857-285-5300

When will Kymera Therapeutics release its fourth quarter and full year 2023 financial results?

Kymera Therapeutics will release its fourth quarter and full year 2023 financial results on February 22, 2024.

What is Kymera Therapeutics' ticker symbol?

Kymera Therapeutics' ticker symbol is KYMR.

What is the focus of Kymera Therapeutics' medicines?

Kymera Therapeutics specializes in small molecule medicines using targeted protein degradation.

How can investors join Kymera Therapeutics' conference call?

Investors can join the conference call at 8:30 a.m. ET by dialing +1 (833) 630-2127 (US) or +1 (412) 317-1846 (International).

Where can investors access the live webcast of Kymera Therapeutics' conference call?

Investors can access the live webcast under 'News and Events' in the Investors section of Kymera Therapeutics' website at www.kymeratx.com.